贝飞达对慢性肝病患者纤维化指标及TNF-α的影响

Influence of Beifeida on chronic liver patient fibrosis target and TNF-α

目的探讨贝飞达在治疗慢性肝病患者时,对血清HA、NL、IV-C及TNF-α的影响。方法血清HA、LN、IV-及TNF-α检测采用放免法。结果60例肝功能减退者,经3个月贝飞达治疗与对照组比较,HA、LN、IV-C及TNF-α值下降水平平均低于对照组,经统计学处理差异有显著性。结论应用微生态调节剂贝飞达对慢性肝病患者进行抗纤维化治疗,通过调整肠道菌群失调,控制内毒素血症,可以降低血清HA、LN、IV-C及TNF-α水平,从而达到预防和控制纤维化的目的。

Objective To study the influence of serum HA, LN, IV-C, TNF-α by Beifeida curing chronic hepatic patients. Method Serum levels of HA, LN, IV-C TNF-α were measured by RIA in patients with therapy group and control group. Results The serum levels of HA, LN, IV-C, TNF-α, were lower after oral Beifeida for three months than that before therapy in 60 chronic hepatic function decreasence group. There was obvious difference in statistics between the therapy group and control group. Conclusion Microecological adjustment drug,Beifeida as an antifibrosis therapy on chronic hepatic patients, is able to regulate alteration of intestinal flora, control ETM, degrade serum levels of HA, LN, IV-C, TNF-α, achieving the destination of precautioning and controlling fibrosis.